阿扎胞苷是吡哆醇难治性女性X连锁铁粒幼细胞性贫血的潜在治疗药物
本研究从吡哆醇难治性X连锁铁粒幼细胞性贫血(XLSA)家系中一母两女的周围血细胞建立诱导多能干细胞(iPSC)系,发现活性突变型ALAS2 iPSC的红系分化、珠蛋白与HO-1表达及血红素合成严重受损,阿扎胞苷可重新激活沉默的野生型ALAS2等位基因并改善红系分化缺陷,提示其为此类女性XLSA的潜在新治疗药物。
要点
- 活性突变型ALAS2 iPSC红系分化潜能较活性野生型严重受损,部分细胞呈发育异常和核周铁沉积。
- 活性突变型红系母细胞珠蛋白、HO-1表达及血红素合成较活性野生型严重受损。
- 阿扎胞苷重新激活活性突变型HPC中沉默的野生型ALAS2等位基因并改善红系分化缺陷。
核心结论
- 阿扎胞苷是女性XLSA的潜在新型治疗药物。
- 患者特异性iPSC平台为XLSA提供了新的生物学和治疗见解。
研究设计与样本
- 从吡哆醇难治性XLSA家系中一母两女的周围血细胞成功建立活性野生型和突变型ALAS2诱导多能干细胞(iPSC)系,该家系与杂合ALAS2错义突变(R227C)相关。
主要发现
- 活性突变型iPSC系的红系分化潜能较活性野生型iPSC系严重受损。
- 多数活性突变型iPSC来源红系母细胞呈不成熟形态表型,部分显示发育异常和核周铁沉积。
- 活性突变型红系母细胞的珠蛋白和HO-1表达及血红素合成较活性野生型红系母细胞严重受损。
- 活性突变型红系母细胞中与红系母细胞成熟和核浓缩相关的基因表达显著降低,重现了成熟缺陷。
- 给予δ-氨基乙酰丙酸改善了活性突变型iPSC来源造血祖细胞(HPC)的红系分化能力和血红蛋白表达。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
X-linked sideroblastic anemia (XLSA) is associated with mutations in the erythroid-specific δ-aminolevulinic acid synthase (ALAS2) gene. Treatment of XLSA is mainly supportive, except in patients who are pyridoxine responsive. Female XLSA often represents a late onset of severe anemia, mostly related to the acquired skewing of X chromosome inactivation. In this study, we successfully generated active wild-type and mutant ALAS2-induced pluripotent stem cell (iPSC) lines from the peripheral blood cells of an affected mother and 2 daughters in a family with pyridoxine-resistant XLSA related to a heterozygous ALAS2 missense mutation (R227C). The erythroid differentiation potential was severely impaired in active mutant iPSC lines compared with that in active wild-type iPSC lines. Most of the active mutant iPSC-derived erythroblasts revealed an immature morphological phenotype, and some showed dysplasia and perinuclear iron deposits. In addition, globin and HO-1 expression and heme biosynthesis in active mutant erythroblasts were severely impaired compared with that in active wild-type erythroblasts. Furthermore, genes associated with erythroblast maturation and karyopyknosis showed significantly reduced expression in active mutant erythroblasts, recapitulating the maturation defects. Notably, the erythroid differentiation ability and hemoglobin expression of active mutant iPSC-derived hematopoietic progenitor cells (HPCs) were improved by the administration of δ-aminolevulinic acid, verifying the suitability of the cells for drug testing. Administration of a DNA demethylating agent, azacitidine, reactivated the silent, wild-type ALAS2 allele in active mutant HPCs and ameliorated the erythroid differentiation defects, suggesting that azacitidine is a potential novel therapeutic drug for female XLSA. Our patient-specific iPSC platform provides novel biological and therapeutic insights for XLSA.
引用
- Morimoto Y, Chonabayashi K, Kawabata H, et al. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia. Blood Adv. 2022. PMID: 34781359. doi:10.1182/bloodadvances.2021005664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。